# Roivant Sciences Ltd.: overview

ROIV · Nasdaq · CIK 1635088 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/roiv.md) · [Financials](/companies/roiv/financials.md) · [Filings](/companies/roiv/filings.md) · [Insiders](/companies/roiv/insiders.md)

Latest reported revenue: [$1.4m](/filings/0001635088-26-000090.md) for Q1 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001635088-26-000090).

## Last eight quarters

| Line item | Unit | Q2 FY2024 (2024-09-30) | Q3 FY2024 (2024-12-31) | Q4 FY2024 (2025-03-31) | Q1 FY2025 (2025-06-30) | Q2 FY2025 (2025-09-30) | Q3 FY2025 (2025-12-31) | Q4 FY2025 (2026-03-31) | Q1 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.5](/filings/0001635088-25-000016.md) | [9.0](/filings/0001635088-26-000011.md) | [7.6 d](/filings/0001635088-26-000061.md) | [2.2](/filings/0001635088-26-000090.md) | [1.6](/filings/0001635088-25-000016.md) | [2.0](/filings/0001635088-26-000011.md) | [2.5 d](/filings/0001635088-26-000061.md) | [1.4](/filings/0001635088-26-000090.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(7636.0%)](/filings/0001635088-25-000016.md) | [(3042.6%)](/filings/0001635088-26-000011.md) | [(3764.4%) d](/filings/0001635088-26-000061.md) | [(13130.0%)](/filings/0001635088-26-000090.md) | [(19492.9%)](/filings/0001635088-25-000016.md) | [(16966.1%)](/filings/0001635088-26-000011.md) | [16477.8% d](/filings/0001635088-26-000061.md) | [(25380.9%)](/filings/0001635088-26-000090.md) |
| Net margin | % | [(5143.8%)](/filings/0001635088-25-000016.md) | [1878.3%](/filings/0001635088-26-000011.md) | [(2727.5%) d](/filings/0001635088-26-000061.md) | [(10292.9%)](/filings/0001635088-26-000090.md) | [(7225.9%)](/filings/0001635088-25-000016.md) | [(13301.2%)](/filings/0001635088-26-000011.md) | [12023.6% d](/filings/0001635088-26-000061.md) | [(13164.8%)](/filings/0001635088-26-000090.md) |
| Diluted EPS | $ per share | [(0.31)](/filings/0001635088-25-000016.md) | [0.23](/filings/0001635088-26-000011.md) | not reported | [(0.33)](/filings/0001635088-26-000090.md) | [(0.17)](/filings/0001635088-25-000016.md) | [(0.38)](/filings/0001635088-26-000011.md) | not reported | [(0.26)](/filings/0001635088-26-000090.md) |
| Free cash flow | $m | [(268) d](/filings/0001635088-25-000016.md) | [(209) d](/filings/0001635088-26-000011.md) | [(173) d](/filings/0001635088-26-000061.md) | [(208)](/filings/0001635088-26-000090.md) | [(194) d](/filings/0001635088-25-000016.md) | [(201) d](/filings/0001635088-26-000011.md) | [(165) d](/filings/0001635088-26-000061.md) | [(271)](/filings/0001635088-26-000090.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2022-03-31) | FY2022 (2023-03-31) | FY2023 (2024-03-31) | FY2024 (2025-03-31) | FY2025 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [55.3](/filings/0001140361-23-031798.md) | [31.5](/filings/0001140361-25-020715.md) | [32.7](/filings/0001635088-26-000061.md) | [29.1](/filings/0001635088-26-000061.md) | [8.3](/filings/0001635088-26-000061.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(2444.8%)](/filings/0001140361-23-031798.md) | [(2875.9%)](/filings/0001140361-25-020715.md) | [13746.9%](/filings/0001635088-26-000061.md) | [(3453.3%)](/filings/0001635088-26-000061.md) | [(6235.7%)](/filings/0001635088-26-000061.md) |
| Net margin | % | [(1528.9%)](/filings/0001140361-23-031798.md) | [(3200.2%)](/filings/0001140361-25-020715.md) | [13294.2%](/filings/0001635088-26-000061.md) | [(592.0%)](/filings/0001635088-26-000061.md) | [(3629.2%)](/filings/0001635088-26-000061.md) |
| Diluted EPS | $ per share | [(1.26)](/filings/0001140361-23-031798.md) | [(1.42)](/filings/0001140361-25-020715.md) | [5.23](/filings/0001635088-26-000061.md) | [(0.24)](/filings/0001635088-26-000061.md) | [(0.54)](/filings/0001635088-26-000061.md) |
| Free cash flow | $m | [(695)](/filings/0001140361-23-031798.md) | [(856)](/filings/0001140361-25-020715.md) | [(767)](/filings/0001635088-26-000061.md) | [(844)](/filings/0001635088-26-000061.md) | [(759)](/filings/0001635088-26-000061.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/roiv/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-20 | [Venker Eric](/insiders/1801917.md) | President & Immunovant CEO, Officer | Sale (S) | 14,144 | $35.42 | $501.0k | [Form 4](/filings/0001635088-26-000116.md) |
| 2026-10-20 | [Venker Eric](/insiders/1801917.md) | President & Immunovant CEO, Officer | Sale (S) | 185,856 | $35.09 | $6.5m | [Form 4](/filings/0001635088-26-000116.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

None of the funds in coverage reports a position in its latest 13F.

## Recent filings

[All 964 filings](/companies/roiv/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-21 | 07:05 ET | [8-K](/filings/0001140361-26-040332.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-040332 |
| 2026-10-05 | 21:02 ET | [SCHEDULE 13D/A](/filings/0001140361-26-038693.md) | Ownership report, active investor, amended | 0001140361-26-038693 |
| 2026-09-18 | 07:14 ET | [8-K](/filings/0001635088-26-000095.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001635088-26-000095 |
| 2026-09-08 | 09:15 ET | [8-K](/filings/0001140361-26-035859.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-035859 |
| 2026-08-28 | 16:31 ET | [8-K](/filings/0001140361-26-034854.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-034854 |
| 2026-08-27 | 17:24 ET | [8-K](/filings/0001140361-26-034735.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-034735 |
| 2026-08-06 | 07:28 ET | [10-Q](/filings/0001635088-26-000090.md) | Quarterly report, period 2026-06-30 | 0001635088-26-000090 |
| 2026-08-06 | 07:13 ET | [8-K](/filings/0001635088-26-000088.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001635088-26-000088 |
| 2026-07-29 | 07:00 ET | [DEF 14A](/filings/0001140361-26-029955.md) | Proxy statement, period 2026-09-16 | 0001140361-26-029955 |
| 2026-05-20 | 07:17 ET | [10-K](/filings/0001635088-26-000061.md) | Annual report, period 2026-03-31 | 0001635088-26-000061 |

## Latest annual report

[Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001635088-26-000061.md), filed May 20, 2026.

## Forecast league

Q2 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/62694400-3e1f-45f7-a2de-df89e34ec9e5)

## About the filer

- CIK: 1635088
- Tickers: ROIV
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: D0
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 18:30 ET. No prices; not investment advice.